<DOC>
	<DOCNO>NCT01274481</DOCNO>
	<brief_summary>This study examine hypothesis iloprost maintain improve ventilation perfusion match patient pulmonary hypertension ARDS/ALI reflect 1 ) improve PaO2/FIO2 ratio calculate measure arterial blood gas obtain iloprost administration , 2 ) improvement lung compliance , 3 ) improvement ventilatory equivalent oxygen CO2 measure expire gas analysis .</brief_summary>
	<brief_title>Iloprost Effects Gas Exchange Pulmonary Mechanics</brief_title>
	<detailed_description>Purpose/hypothesis This study examine hypothesis iloprost maintain improve ventilation perfusion match patient pulmonary hypertension ARDS/ALI reflect 1 ) improve PaO2/FIO2 ratio calculate measure arterial blood gas obtain iloprost administration , 2 ) improvement lung compliance , 3 ) improvement ventilatory equivalent oxygen CO2 measure expire gas analysis . Experimental design Twenty patient pulmonary hypertension ARDS/ALI enrol . This 2-3 hour study conduct single day patient 's baseline measurement obtain prior iloprost administration compare measurement obtain 30 minute 2 hour Iloprost inhalation . While critically ill virtue underlie illness , patient clinically stable precede 2 hour prior entry study evidence airway pressure arterial O2 saturation vary le 10 % ventilator setting . Proposed procedure After baseline measurement obtain , 10 mcg iloprost administer via nebulizer inspiratory line ventilator . Vital sign include blood pressure heart rate , respiratory rate arterial saturation pulse oximetry monitor baseline q 5 minute inhalation iloprost . Thirty ( 30 ) minute administration iloprost gas exchange , pulmonary function arterial blood gas measurement repeat described . Patients remain clinically stable evidenced fall arterial PO2 &lt; 5 mm Hg , fall systemic blood pressure &lt; 10 % increase heart rate &lt; 10 beats/min well absence symptom 30 minute inhalation 20 mcg iloprost receive second dose 20 mcg . Vital sign continue monitor continuously 30 minute second dose iloprost , pulmonary measurement repeat . All patient monitor continuously least 2 hour final dose iloprost pulmonary testing repeat final time 2 hour last administration iloprost . Patients deem complete study 2 hour provide vital sign return within 10 % baseline value . Importance knowledge reasonably expect result research A positive result pilot study provide strong rationale lead large long-term study examine effect continuous iloprost therapy several day pulmonary hemodynamics , gas exchange , outcome patient ARDS/ALI . Markers inflammation ( IL-6 IL-8 ) , coagulation ( thrombin-antithrombin complex D-dimer ) collagen formation ( TGF* procollagen peptide III ) lung BAL fluid would monitor demonstrate iloprost 's potential beneficial effect lung remodel devastate disorder . If research involve minimal risk , describe research plan monitor data collect ensure safety participant . Data safety monitor board meet first six patient determine whether continue .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Lung Injury</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>1 . Pulmonary hypertension evidence : In patient pulmonary artery catheter , mean pulmonary arterial pressure great 25 mmHg pulmonary capillary wedge pressure less equal 15 mmHg , Echocardiographic evidence pulmonary arterial hypertension include PA systolic pressure great 35 mmHg , patient PA systolic estimate technical reason , RV dilatation and/or decrease RV function presence normal LV function . 2 . ARDS/ALI indicate : Diffuse pulmonary infiltrates involve least three four quadrant chest xray . PaO2/FIO2 le 300 mechanical ventilation . Recognized cause ARDS/ALI Absence clinical evidence leave atrial hypertension 3. presence arterial line pressure monitor blood sampling , 4. ability obtain informed consent patient next kin . 1. clinical instability evidence change ventilator setting medication within precede hour , 2. presence leave ventricular dysfunction and/or leave atrial enlargement cardiac echo , catheterization , 3 . Liver failure ( ChildPugh Class B C ) 4 . Renal failure dialysis 5 . Pregnancy : female childbearing potential negative pregnancy test allow enroll 6 . Systolic blood pressure le 85 mm Hg need pressor first 10 patient ; review first 10 patient DMSB , patient norepinephrine ( without additional pressor ) dose less 0.2 mcg/kg/min may enrol DMSB find evidence iloprost induced systemic hypotension first 10 patient 7 . Thrombocytopenia , bleed diathesis active bleeding 8 . Asthma/Severe bronchospasm 9 . Age &lt; 18 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Acute Respiratory Distress Syndrome</keyword>
	<keyword>Acute Lung Injury</keyword>
	<keyword>pulmonary hypertension</keyword>
	<keyword>oxygenation</keyword>
	<keyword>lung mechanic</keyword>
	<keyword>gas exchange</keyword>
</DOC>